Sagimet Biosciences Inc. (SGMT)
| Market Cap | 190.95M +161.3% |
| Revenue (ttm) | n/a |
| Net Income | -51.04M |
| EPS | -1.58 |
| Shares Out | 32.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 252,133 |
| Open | 5.85 |
| Previous Close | 5.87 |
| Day's Range | 5.68 - 5.96 |
| 52-Week Range | 2.67 - 11.41 |
| Beta | 3.21 |
| Analysts | Strong Buy |
| Price Target | 26.38 (+350.17%) |
| Earnings Date | May 14, 2026 |
About SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for SGMT stock is "Strong Buy." The 12-month stock price target is $26.38, which is an increase of 350.17% from the latest price.
News
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metaboli...
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metaboli...
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026 S...
Sagimet Biosciences Transcript: Leerink Global Healthcare Conference 2026
FASN inhibition is being advanced for MASH and acne, with Denifanstat as the lead candidate and a combination with Resmetirom targeting F4 cirrhotic MASH. Phase II studies for both MASH and next-gen acne programs are set for late 2024, and Chinese partner data may accelerate U.S. acne development.
Sagimet Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
Combination therapy for MASH is advancing with denifanstat and resmetirom, supported by strong preclinical synergy and phase I safety data. The acne program targets moderate to severe cases with a novel oral FASN inhibitor, leveraging insights from Asian partner trials. Milestone payments and a solid cash position support ongoing development.
Sagimet Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Denifanstat demonstrated robust efficacy and safety in both MASH and acne, with phase II and III data supporting its differentiated mechanism. The combination with resmetirom is advancing in MASH, while next-gen FASN inhibitor TVB-3567 and Chinese regulatory milestones in acne are expected to drive further value.
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
SAN MATEO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Sagimet Biosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Denifanstat, a novel FASN inhibitor, shows strong efficacy and safety in both MASH and acne, with pivotal studies ongoing and regulatory milestones expected in China and the U.S. A next-gen molecule is advancing for acne, and the company is well-funded through 2027.
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
SAN MATEO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The exceptional efficacy of denifansta...
Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor
Dr. George Kemble, former AstraZeneca executive, to advise the Company on immunological and viral strategies for its novel cancer treatment platform Dr. George Kemble, former AstraZeneca executive, to...
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
The combination of denifanstat and resmetirom was generally well-tolerated Pharmacokinetic (PK) results support further development of the combination A Phase 2 trial of a denifanstat/resmetirom combi...
Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration
SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, d...
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Sagimet Biosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference
A differentiated FASN inhibitor is advancing in both MASH and acne, with strong clinical data in advanced fibrosis and promising results in Chinese acne trials. Combination therapy and next-gen molecules are central to future plans, though significant funding is needed for late-stage studies.
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
SAN MATEO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Sagimet Biosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
FASN inhibitor denifanstat shows strong efficacy in advanced MASH and moderate to severe acne, with a favorable safety profile. Combination with resmetirom is advancing, and next-gen acne programs are underway. Both MASH and acne markets are poised for significant growth.
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025
A secondary analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis, inflammation and steatosis in advanced qF4 MASH patients as measured by artificial intelligence (AI) digit...
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announce...
Sagimet Biosciences Transcript: H.C. Wainwright Liver Disease Virtual Conference
FASN inhibition with denifanstat shows significant efficacy in advanced MASH and acne, with unique direct effects on fibrosis and inflammation. Digital pathology and non-invasive endpoints are shaping regulatory pathways, while combination regimens and new oral acne therapies offer strong future potential.
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III ra...
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...